Concepedia

Author

Heng Zhou

Merck & Co., Inc., Rahway, NJ, USA (United States)ORCID

Also Known As

H. Zhou, Heng Zhou, Zhou, Heng

51

Publications

537

Citations

9

H-Index

33

Concepts

All Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)The University of Texas MD Anderson Cancer CenterDecision Sciences (United States)
HZ

About

Heng Zhou is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, oncology, and clinical trial design.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

3

3

163

2

Business

1

1

23

3

Engineering

1

1

121

4

Health Sciences

1

1

11

5

Public Health

1

1

121

Heng Zhou

×

7

Publications

365

Citations

7

H-Index

YearCitations

BOP2: Bayesian optimal design for phase II clinical trials with simple and complex endpoints

Heng Zhou, J. Jack Lee, Ying Yuan

Statistics in Medicine

2017

121

Accuracy, Safety, and Reliability of Novel Phase I Trial Designs

Heng Zhou, Ying Yuan, Lei Nie

Clinical Cancer Research

2018

116

Comparison of Duration of Response vs Conventional Response Rates and Progression-Free Survival as Efficacy End Points in Simulated Immuno-oncology Clinical Trials

Chen Hu, Meihua Wang, Cai Wu,

JAMA Network Open

2021

32

Bayesian optimal phase <scp>II</scp> clinical trial design with time‐to‐event endpoint

Heng Zhou, Cong Chen, Linda Sun,

Pharmaceutical Statistics

2020

31

Treatment with a retinoic acid-inducible gene I (RIG-I) agonist as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: results from two phase 1 studies

Víctor Moreno, Emiliano Calvo, Mark R. Middleton,

Cancer Immunology Immunotherapy

2022

31

Optimal two-stage designs for exploratory basket trials

Heng Zhou, Fang Liu, Cai Wu,

Contemporary Clinical Trials

2019

23

Accuracy and Safety of Novel Designs for Phase I Drug-Combination Oncology Trials

Rong Liu, Ying Yuan, Suman Sen,

Statistics in Biopharmaceutical Research

2022

11

Page 1